Safety Assessment of the Dietary Supplement OxyELITE™ Pro (New Formula) in Inbred and Outbred Mouse Strains

Overview

Journal Food Chem Toxicol

Specialties Nutritional Sciences
Toxicology

Date 2017 Aug 28

PMID 28843594

Citations 10

Authors

Isabelle R Miousse

Charles M Skinner

Haixia Lin

Laura E Ewing

Stanley D Kosanke

D Keith Williams

Bharathi Avula

Ikhlas A Khan

Mahmoud A ElSohly

Bill J Gurley

Igor Koturbash

Affiliations

Soon will be listed here.

Abstract

Herbal dietary supplements have gained wide acceptance as alternatives to conventional therapeutic agents despite concerns regarding their efficacy and safety. In 2013, a spate of severe liver injuries across the United States was linked to the dietary supplement OxyELITE Pro-New Formula (OEP-NF), a multi-ingredient product marketed for weight loss and exercise performance enhancement. The principal goal of this study was to assess the hepatotoxic potential of OEP-NF in outbred and inbred mouse models. In an acute toxicity study, significant mortality was observed after administering 10X and 3X mouse-equivalent doses (MED) of OEP-NF, respectively. Increases in liver/body weight ratio, ALT and AST were observed in female B6C3F mice after gavaging 2X and 1.5X MED of OEP-NF. Similar findings were observed in a 90-day feeding study. These alterations were paralleled by altered expression of gene- and microRNA-signatures of hepatotoxicity, including Cd36, Nqo1, Aldoa, Txnrd1, Scd1 and Ccng1, as well as miR-192, miR-193a and miR-125b and were most pronounced in female B6C3F mice. Body weight loss, observed at week 1, was followed by weight gain throughout the feeding studies. These findings bolster safety and efficacy concerns for OEP-NF, and argue strongly for implementation of pre-market toxicity studies within the dietary supplement industry.

Citing Articles

A Combined Approach for Rapid Dereplication of Herb-Drug Interaction Causative Agents in Botanical Extracts-A Molecular Networking Strategy To Identify Potential Pregnane X Receptor (PXR) Modulators in Yohimbe.

Annam S, Neal W, Pandey P, Avula B, Katragunta K, Husain I ACS Omega. 2025; 9(52):51394-51407.

PMID: 39758619 PMC: 11696432. DOI: 10.1021/acsomega.4c08293.

Human quad liver-on-chip system as a tool toward bridging the gap between animals and humans regarding toxicology and pharmacology of a cannabidiol-rich cannabis extract.

Ewing L, Skinner C, McGill M, Kennon-McGill S, Clement K, Quick C Drug Chem Toxicol. 2024; :1-8.

PMID: 39155655 PMC: 11836190. DOI: 10.1080/01480545.2024.2388292.

Hepatotoxicity due to herbal dietary supplements: Past, present and the future.

Gurley B, McGill M, Koturbash I Food Chem Toxicol. 2022; 169:113445.

PMID: 36183923 PMC: 11404749. DOI: 10.1016/j.fct.2022.113445.

Safety and Molecular-Toxicological Implications of Cannabidiol-Rich Cannabis Extract and Methylsulfonylmethane Co-Administration.

Kutanzi K, Ewing L, Skinner C, Quick C, Kennon-McGill S, McGill M Int J Mol Sci. 2020; 21(20).

PMID: 33096940 PMC: 7656295. DOI: 10.3390/ijms21207808.

Severe Acute Hepatitis Attributed to the Herbal and Dietary Supplement OxyELITE Pro.

Fontana R Clin Liver Dis (Hoboken). 2019; 14(2):45-48.

PMID: 31508218 PMC: 6726377. DOI: 10.1002/cld.809.

References

Singh R, Banerjee S, Rao A . Effect of Aegle marmelos on biotransformation enzyme systems and protection against free-radical-mediated damage in mice. J Pharm Pharmacol. 2000; 52(8):991-1000. DOI: 10.1211/0022357001774714. View

Siegel D, Ross D . Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med. 2000; 29(3-4):246-53. DOI: 10.1016/s0891-5849(00)00310-5. View

Skibola C, Smith M . Potential health impacts of excessive flavonoid intake. Free Radic Biol Med. 2000; 29(3-4):375-83. DOI: 10.1016/s0891-5849(00)00304-x. View

Schneiderhan W, Zhao J, Grunert A, Nussler A, Weidenbach H, Menke A . Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology. 2001; 34(4 Pt 1):729-37. DOI: 10.1053/jhep.2001.27828. View

Strassburg A, Strassburg C, Manns M, Tukey R . Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol. 2002; 61(2):320-5. DOI: 10.1124/mol.61.2.320. View

Kanda T, Yokosuka O, Okada O, Suzuki Y, Saisho H . Severe hepatotoxicity associated with Chinese diet product 'Onshidou-Genbi-Kounou'. J Gastroenterol Hepatol. 2003; 18(3):354-5. DOI: 10.1046/j.1440-1746.2003.02952.x. View

Bras G, JELLIFFE D, STUART K . Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica. AMA Arch Pathol. 1954; 57(4):285-300. View

Schilter B, Andersson C, Anton R, Constable A, Kleiner J, OBrien J . Guidance for the safety assessment of botanicals and botanical preparations for use in food and food supplements. Food Chem Toxicol. 2003; 41(12):1625-49. DOI: 10.1016/s0278-6915(03)00221-7. View

. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist. 2004; 69(28):6787-854. View

10.

Haller C, Jacob 3rd P, Benowitz N . Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther. 2004; 75(4):259-73. DOI: 10.1016/j.clpt.2003.11.375. View

11.

Le Corre P, Parmer R, Kailasam M, Kennedy B, Skaar T, Ho H . Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. 2004; 76(2):139-53. DOI: 10.1016/j.clpt.2004.04.010. View

12.

Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2004; 5(1):6-13. DOI: 10.1038/sj.tpj.6500285. View

13.

Derlet R, Tseng J, Albertson T . Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med. 1992; 10(3):211-6. DOI: 10.1016/0735-6757(92)90211-F. View

14.

Minami K, Saito T, Narahara M, Tomita H, Kato H, Sugiyama H . Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats. Toxicol Sci. 2005; 87(1):296-305. DOI: 10.1093/toxsci/kfi235. View

15.

McNamara R, Kerans A, ONeill B, Harkin A . Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology. 2005; 50(1):69-80. DOI: 10.1016/j.neuropharm.2005.08.006. View

16.

Bonkovsky H . Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med. 2006; 144(1):68-71. DOI: 10.7326/0003-4819-144-1-200601030-00020. View

17.

Aleksunes L, Goedken M, Manautou J . Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J Gastroenterol. 2006; 12(12):1937-40. PMC: 4087521. DOI: 10.3748/wjg.v12.i12.1937. View

18.

Veerappan A, Miyazaki S, Kadarkaraisamy M, Ranganathan D . Acute and subacute toxicity studies of Aegle marmelos Corr., an Indian medicinal plant. Phytomedicine. 2006; 14(2-3):209-15. DOI: 10.1016/j.phymed.2006.05.004. View

19.

Palming J, Sjoholm K, Jernas M, Lystig T, Gummesson A, Romeo S . The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction. J Clin Endocrinol Metab. 2007; 92(6):2346-52. DOI: 10.1210/jc.2006-2476. View

20.

Dunnick J, Kissling G, Gerken D, Vallant M, Nyska A . Cardiotoxicity of Ma Huang/caffeine or ephedrine/caffeine in a rodent model system. Toxicol Pathol. 2007; 35(5):657-64. PMC: 2104562. DOI: 10.1080/01926230701459978. View